On February 12, 2026, the 2026 China-Netherlands Anti-Cancer Summit was successfully held. The summit was co-organized by China Anti-Cancer Association (CACA), Netherlands Cancer Institute (NCI), and World Association for Integrative Oncology (WAIO). It attracted audiences from China, the United States, the Netherlands, Germany, France, Belgium, Switzerland, Italy, Spain, and other countries, with a total of 12.1 million online views.

The summit featured lectures by Prof. Daiming Fan, President of CACA; Prof. René Bernards, former President of European Association for Cancer Research (EACR); Prof. Haojie Jin from Shanghai Jiao Tong University, Renji Hospital; and Prof. Jacco van Rheenen, Deputy Director of the Netherlands Cancer Institute. Prof. Yunlong Xia, President of the First Affiliated Hospital of Dalian Medical University, served as the Chair of this event, and Prof. Ying Wang, Vice President of CACA, delivered the opening address.

Opening Remarks

In her speech, Prof. Wang welcomed the participating experts from various countries, emphasized the critical role of international collaboration in addressing global cancer challenges, and highlighted the progress made by CACA in promoting cancer diagnosis and treatment guidelines tailored to the Chinese population and building international prevention and control cooperation networks. She noted that the association has held 29 international summits to date and expressed hope that this summit would serve as a cornerstone for long-term cooperation between China and the Netherlands in the fight against cancer. She wished the summit a complete success.

Keynote Speeches

Prof. Fan, President of CACA, President of Asian Oncology Society, and President of WAIO, delivered a keynote speech titled "Development of Holistic Integrative Management of Cancer in China." He systematically elaborated on the innovative concept of Holistic Integrative Medicine (HIM) in China and proposed the core principle of "United, we help those in need from the beginning to the end." He emphasized that medicine should evolve from "evidence-based" to "inquiry-based," and cancer treatment must shift from "fighting cancer" to "controlling cancer" and "preserving life." Prof. Fan also shared CACA's practical explorations in implementing integrative medicine and highlighted the CACA Guidelines for HIM of cancer, which are tailored to China's national conditions.

Prof. Bernards, Professor of Molecular Carcinogenesis at the Netherlands Cancer Institute and former President of EACR, delivered a speech titled "Overactivation of Oncogenic Signaling as A Cancer Treatment Strategy." He proposed a disruptive therapeutic approach, demonstrating how deliberately hyperactivating oncogenic signaling through drug combinations can force colorectal cancer cells into abnormal division and death, offering a novel strategy to overcome drug resistance.

Prof. Jin from Shanghai Jiao Tong University, Renji Hospital, Principal Investigator of the State Key Laboratory of Systems Medicine for Cancer, and Committee Member of CACA's Targeted Therapy Committee, reported on "From Bench to Bedside: Translational Research on Novel Lenvatinib-Based Combination Therapy Strategies ." He systematically presented his team's latest advancements in optimizing targeted drug combinations and intervening in drug resistance mechanisms.

Prof. Rheenen, Deputy Director of the Netherlands Cancer Institute and Senior group Leader at the Oncode Institute, delivered a speech titled "Timing Matters: How Hormonal Rhythms Govern Mutation Clearance, Cancer Initiation, and Treatment Response." He revealed the critical regulatory role of estrous and menstrual cycles in the progression of breast cancer, providing a novel theoretical foundation for time-window-based precision treatment strategies.

Roundtable Discussion

During the roundtable discussion, experts from China and the Netherlands engaged in in-depth exchanges on the coordinated development of globalization and localization in cancer prevention and treatment. Prof. Fan and Prof. Bernards emphasized the central role of international cooperation in cancer prevention and treatment, noting significant population heterogeneity in clinical practices for cancers such as liver and breast cancer between China and Europe. They stressed the need to deepen international collaboration to promote proof-of-concept studies of innovative drugs from Europe and the United States in China, while accelerating the integration of high-quality Chinese clinical research into international guidelines. The experts also discussed the future application of artificial intelligence in drug development and combination therapies, as well as the potential impact of individualized variables such as hormonal cycles on cancer treatment. The experts unanimously agreed that only by breaking down data barriers and building shared platforms can the vision of "patient-centered" precision medicine be truly realized.

The successful convening of the 2026 China-Netherlands Anti-Cancer Summit marks a new milestone in China-Netherlands cancer cooperation and reflects a deeper and broader phase of China-Europe oncology exchanges. Moving forward, CACA will continue to collaborate with global partners to advance the international dissemination and clinical translation of holistic integrative oncology, contributing Chinese wisdom and solutions to the global effort of building a shared community for human health.